NCT04200404 - A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 13, 2019

Primary Completion Date

May 13, 2021

Study Completion Date

August 18, 2021

Conditions

Advanced Refractory Solid Tumors

Interventions

DRUG

CS1001

One course will last 28 days. CS1001 will be intravenously administered every 4 weeks (Q4W).

DRUG

Regorafenib

One course will last 28 days. Administration will be orally (p.o.) taken at different dose schemes.

Trial Locations (1)

Ashford Cancer Centre Research, Kurralta Park